Citations

Clear

124 citation(s) found for "Storm, A".

The COVID-19 endemic: calm before the storm of paediatric viral respiratory illnesses
Deng, Jiawen , Heybati, Kiyan , Huang, Emma , Zhou, Fangwen , Deng, J , Zhou, F , Garcia, C

Mayo Clinic

QJM: An International Journal of Medicine | November 25, 2022 | Volume: 116 | Issue: 5 | Pages: 329-331

10.1093/qjmed/hcac264 | PMID 36440950 Get It

Endoscopic ultrasound-guided gastroenterostomy for the management of gastric outlet obstruction: A large comparative study with long-term follow-up
Jaruvongvanich, Veeravich , Mahmoud, Tala , Law, Ryan , Levy, Michael J. , Marya, Neil B. , Abboud, Donna Maria , Ghazi, Rabih , Matar, Reem, Rapaka, Babusai , Buttar, Navtej , Truty, Mark J. , Aerts, Maridi , Messaoudi, Nouredin , Kunda, Rastislav , Abboud, Donna M, Abboud, Donna M , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Storm, Andrew C. , Levy, Michael J. , Vargas, Eric J. , Marya, Neil B.

Mayo Clinic

Endoscopy International Open | November 10, 2022 | Volume: 11 | Issue: 01 | Pages: E60-E66

10.1055/a-1976-2279 | PMID 36644538 Get It

Abstract Background and study aims Gastric outlet obstruction (GOO) is traditionally managed with surgical gastroenterostomy (surgical-GE) and enteral stenting (ES). Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is now a third option. Large studies assessing their relative risks and benefits with adequate follow-up are lacking. We conducted a comparative analysis of patients who underwent EUS-GE, ES, or surgical-GE for GOO. Patients and methods In this retrospective comparative cohort study, consecutive patients presenting with GOO who underwent EUS-GE, ES, or surgical-GE at two academic institutions were reviewed and independently cross-edited to ensure accurate reporting. The primary outcome was need for reintervention. Secondary outcomes were technical and clinical success, length of hospital stay (LOS), and adverse events (AEs). Results A total of 436 patients (232 EUS-GE, 131 ES, 73 surgical-GE) were included. The median duration of follow-up of the entire cohort was 185.5 days (interquartile range 55.25–454.25 days). The rate of reintervention in the EUS-GE group was lower than in the ES and surgical-GE groups (0.9 %, 12.2 %, and 13.7 %, P < 0.0001). Technical success was achieved in 98.3 %, 99.2 %, and 100 % (P = 0.58), and clinical success was achieved in 98.3 %, 91.6 %, and 90.4 % (P < 0.0001) in the EUS-GE, ES, and surgical-GE groups, respectively. The EUS-GE group had a shorter LOS (2 days vs. 3 days vs. 5 days, P < 0.0001) and a lower AE rate than the ES and surgical-GE groups (8.6 % vs. 38.9 % vs. 27.4 %, P < 0.0001). Conclusion This large cohort study demonstrates the safety and palliation durability of EUS-GE as an alternative strategy for GOO palliation in select patients.
A novel through-the-scope helix tack-and-suture device for mucosal defect closure following colorectal endoscopic submucosal dissection: a multicenter study
Farha, Jad , Ramberan, Hemchand, Aihara, Hiroyuki , Zhang, Linda Y. , Mehta, Amit , Hage, Camille , Schlachterman, Alexander , Kumar, Anand , Shinn, Brianna , Canakis, Andrew , Kim, Raymond E., Buscaglia, Jonathan M. , Samarasena, Jason , Chang, Kenneth J. , Friedland, Shai , Qumseya, Bashar , Jawaid, Salmaan , Othman, Mohamed O. , Hasan, Muhammad K. , Khashab, Mouen A., Ngamruengphong, Saowanee , group, ESD-Closure working, Storm, Andrew C , Othman, Mohamed O , Canakis, Andrew , D'Souza, Lionel S. , Storm, Andrew C. , Draganov, Peter V. , Yang, Dennis J. , Khashab, Mouen A. , group, ESD-Closure working

Mayo Clinic

Endoscopy | November 3, 2022 | Volume: 55 | Issue: 06 | Pages: 571-577

10.1055/a-1970-5528 | PMID 36323330 Get It

Background Complete closure of large mucosal defects following colorectal endoscopic submucosal dissection (ESD) with through-the-scope (TTS) clips is oftentimes not possible. We aimed to report our early experience of using a novel TTS suturing system for the closure of large mucosal defects after colorectal ESD. Methods We performed a retrospective multicenter cohort study of consecutive patients who underwent attempted prophylactic defect closure using the TTS suturing system after colorectal ESD. The primary outcome was technical success in achieving complete defect closure, defined as a < 5 mm residual mucosal defect in the closure line using TTS suturing, with or without adjuvant TTS clips. Results 82 patients with a median defect size of 30 (interquartile range 25–40) mm were included. Technical success was achieved in 92.7 % (n = 76): TTS suturing only in 44 patients (53.7 %) and a combination of TTS suturing to approximate the widest segment followed by complete closure with TTS clips in 32 (39.0 %). Incomplete/partial closure, failure of appropriate TTS suture deployment, and the need for over-the-scope salvage closure methods were observed in 7.3 % (n = 6). One intraprocedural bleed, one delayed bleed, and three intraprocedural perforations were observed. There were no adverse events related to placement of the TTS suture. Conclusion The TTS suture system is an effective and safe tool for the closure of large mucosal defects after colorectal ESD and is an alternative when complete closure with TTS clips alone is not possible.
Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones: a comparative prospective study
Rizk, Monika, Gomez-Villa, Jacky, Edwards, Phillip K , Jaruvongvanich, Veeravich , Acosta, Andrés , Lake, David S. , Fidler, Jeff L. , Bharucha, Adil E. , Camilleri, Michael , Vargas, Eric J , Acosta, Andres , Lake, David, Fidler, Jeff, Bharucha, A E , Camilleri, M , Abu Dayyeh, Barham K , Vargas, Eric J. , Storm, Andrew C. , Fidler, Jeff L. , Dayyeh, Barham K. Abu

Mayo Clinic

Gut | October 14, 2022 | Volume: 72 | Issue: 6 | Pages: 1073-1080

10.1136/gutjnl-2022-327816 | PMID 36241388 Get It

Objective Endoscopic sleeve gastroplasty (ESG) has gained global adoption but our understanding of its mechanism(s) of action and durability of efficacy is limited. We sought to determine changes in gastric emptying (GE), gastric motility (GM), hormones and eating behaviours after ESG. Design A priori-designed single-centre substudy of a large US randomised clinical trial, adults with obesity were randomised to ESG or lifestyle interventions (LS) alone. We measured GE, hormones and weight loss and assessed eating behaviours. In a subset of ESG patients, we assessed GM. The primary outcome was the change in T1/2 (min) at 3 months, and secondary outcomes were changes in weight, GE, GM, hormones and eating behaviours. We used t-test analyses and regression to determine the association between GE and weight loss. Results 36 (ESG=18; LS=18) participated in this substudy. Baseline characteristics were similar between the two groups. At 3 months, T1/2 was delayed in the ESG group (n=17) compared with the LS group (n=17) (152.3±47.3 vs 89.1±27.9; p<0.001). At 12 months, T1/2 remained delayed in the ESG group (n=16) vs control group (n=14) (137±37.4 vs 90.1±23.4; p<0.001). Greater delays in GE at 3 months were associated with greater weight loss. GM was preserved and fasting ghrelin, glucagon-like peptide 1 and polypeptide YY significantly increased 18 months after ESG. Conclusion ESG promotes weight loss through several key mechanistic pathways involving GE and hormones while preserving GM. These findings further support clinical adoption of this technique for the management of obesity. Trial registration number NCT03406975.
Endoscopic Ultrasound-Guided Gastrojejunostomy for Superior Mesenteric Artery Syndrome Secondary to Rapid Weight Loss
Mahmoud, Tala , Akiki, Karl, Law, Ryan , Law, Ryan J, Storm, Andrew C. , Akiki, Karl

Mayo Clinic

ACG Case Reports Journal | October 6, 2022 | Volume: 9 | Issue: 10 | Pages: e00868

10.14309/crj.0000000000000868 | PMID 36212239 Get It

ABSTRACT A 19-year-old man diagnosed with diffuse large B-cell lymphoma undergoing chemotherapy presented for recurrent emesis and weight loss. Imaging studies of the abdomen demonstrated features of superior mesenteric artery syndrome. The patient deferred conservative treatment options and was deemed not to be a surgical candidate. Endoscopic ultrasound-guided gastroenterostomy using a lumen-apposing metal stent was performed to bypass the obstruction. Subsequently, the patient's oral intake and weight significantly improved. The stent was removed 6 months after placement with resolution of superior mesenteric artery syndrome symptoms.
Histological assessment of new cholangioscopy-guided forceps in ERCP biliary stricture sampling: a blinded comparative study
Chen, Zongming Eric, Abusaleh, Rami R., Martin, John A. , Law, Ryan , Levy, Michael J. , Petersen, Bret T. , Law, Ryan J, Petersen, Bret, Vargas, Eric J. , Wang, Yaohong , Abusaleh, Rami , Storm, Andrew C. , Dayyeh, Barham K. Abu , Levy, Michael J. , Petersen, Bret T. , Chandrasekhara, Vinay

Mayo Clinic

Endoscopy International Open | September 14, 2022 | Volume: 10 | Issue: 09 | Pages: E1233-E1237

10.1055/a-1897-4686 | PMID 36118635 Get It

Abstract Background and study aims Obtaining quality tissue during ERCP biliary stricture sampling is of paramount importance for a timely diagnosis. While single-operator cholangioscopy (SOC)-guided biopsies have been suggested to be the superior biliary tissue acquisition modality given direct tissue visualization, less is known about the specimen histological quality. We aimed to analyze the specimen quality of SOC biopsies and compare the new generation forceps with prior “legacy” forceps. Patients and methods Patients who underwent SOC from January 2017-August 2021 for biliary sampling were reviewed. In February 2020, the SOC-guided biopsy forceps were changed from legacy SpyBite to the SpyBite Max forceps (max). Specimens were assessed by blinded pathologists for crush artifact (none, mild, or severe) and gross size (greatest dimension in mm). Crush artifact and gross size were compared between the two groups. The diagnostic performance characteristics for cholangiocarcinoma (CCA), were assessed in an exploratory fashion. Results Eighty-one patients (max = 27, legacy = 54) with similar baseline characteristics were included in this study. On blinded pathological assessment, 58 % had crush artifact, without significant differences between the two groups (Max 63 % vs. Legacy 56 %; P = 0.64). A similar mean specimen size was found (max 3 mm vs. legacy 3.2 mm; P = 0.24). The overall prevalence of CCA was 40 %. The sensitivity, specificity, positive predictive value, and negative predictive value of the entire cohort using a combination of cytology, fluorescence in situ hybridization, and SOC-guided biopsies were 78.1 %, 91.8 %, 86.2 %, and 86.5 %, respectively. No difference between legacy or max groups was found. Conclusions A high rate of crush artifact was found in SOC-guided biopsy specimens. Further investigation regarding proper biopsy technique and handling is necessary to increase the diagnostic yield with SOC-guided biopsies.
Future of Metabolic Endoscopy
Ghazi, Rabih , Abboud, Donna Maria , Razak, Farah Abdul, Mahmoud, Tala , Abboud, Donna M , Vargas, Eric J. , Storm, Andrew C. , Chandrasekhara, Vinay , Dayyeh, Barham K. Abu

Mayo Clinic

Journal of Digestive Endoscopy | September 13, 2022 | Volume: 13 | Issue: 03 | Pages: 170-178

10.1055/s-0042-1754335 Get It

AbstractObesity has been escalating as one of the worst public health epidemics. Conservative therapies including lifestyle modifications and weight loss medications have limited efficacy and long-term sustainability. Bariatric surgeries, although effective, remain underutilized due to their cost, safety concerns, and patient acceptance. In the past two decades, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as safe, effective, and less invasive options for the treatment of obesity and its comorbidities, with recent studies reporting favorable outcomes in terms of weight loss and metabolic parameters. This article reviews the major and newly developed EBMTs, with emphasis on their metabolic effects and potential use in the management of metabolic conditions.
Use of an intragastric trocar to perform a novel stapling procedure for reflux disease
Bofill-García, Aliana, Mahmoud, Tala , Rapaka, Babusai , Lescalleet, Kristin, AbiMansour, Jad P. , Lescalleet, Kristin E, Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | August 30, 2022 | Volume: 10 | Issue: 11 | Pages: E1508-E1513

10.1055/a-1933-6573 | PMID 36397862 Get It

Abstract Background and study aims A percutaneous intragastric trocar (PIT) enables intraluminal use of laparoscopic tools and helps overcome traditional limitations of endoscopy. The aim of this study was to determine the efficacy of using a PIT to perform an anti-reflux stapling procedure. Materials and methods Trocars were placed in four animals and an articulating stapler was used to perform fundoplication under endoscopic guidance. Animals were monitored for 14 days post-procedure. Functional lumen imaging of the esophagogastric junction (EGJ) was performed at baseline, immediately post-intervention, and at 14 days. Results The procedure was successful in all animals who survived to day 14 without distress or significant adverse events. Baseline EGJ distensibility was 5.0 ± 1.2 mm2/mmHg, 2.7 ± 0.7 mm2/mmHg post-procedurally, and 3.0 ± 0.8mm2/mmHg on day 14. Average change in distensibility pre- and post-procedure was –2.3 ± 1.8 mm2/mmHg (95 % confidence interval [CI] –0.5 to 5.1, P = 0.08) while change in pre- and day 14 distensibility was –2.0 ± 1.4 mm2/mmHg (95 % CI –0.1 to 4.2, P = 0.06). Conclusions An intragastric trocar allows for use of large-diameter laparoscopic instruments to safely and effectively perform endoluminal fundoplication with anti-reflux properties that persist for at least 14 days.
Effects on physiologic measures of appetite from intragastric balloon and endoscopic sleeve gastroplasty: results of a prospective study
Rapaka, Babusai , Maselli, Daniel B. , López-Nava, Gontrand, Bautista-Castaño, Inmaculada , Jaruvongvanich, Veeravich , Matar, Reem , Vargas, Eric J. , Storm, Andrew C. , Acosta, Andrés , Dayyeh, Barham K. Abu

Mayo Clinic

Chinese Medical Journal | July 5, 2022 | Volume: 135 | Issue: 10 | Pages: 1234-1241

10.1097/cm9.0000000000002097 | PMID 35788090 Get It

Abstract Background: Endoscopic bariatric therapies can help address widening management gaps in obesity. Their ability to facilitate weight loss is largely tied to influences on appetite through perturbations of gastric emptying and accommodation. As these tools gain traction in obesity therapy, their physiologic underpinnings require exploration, which may enhance efficacy, tolerance, and patient-tailored care. Methods: We prospectively assessed consecutive subjects with fluid-filled intragastric balloons (IGBs) (n = 18) placed between October 2016 and June 2017 or underwent endoscopic sleeve gastroplasty (ESG) (n = 23) from March 2018 to June 2018. Patients underwent physiologic appraisal at 3 months with 13C-spirulina-based gastric emptying breath test to determine time to half emptying (T50), as well as maximum tolerated volume (MTV) of a standard nutrient drink test. Changes in T50 and MTV at 3 months were compared with percent total body weight loss (%TBWL) at 3 and 6 months using best-fit linear regression. Results: The change in T50 at 3 months correlated with %TBWL at 3 months for IGB (P = 0.01) and ESG (P = 0.01) but with greater impact on %TBWL in IGB compared to ESG (R 2 = 0.42 vs. 0.26). Change in T50 at 3 months was predictive of weight loss at 6 months for IGB (P = 0.01) but not ESG (P = 0.11). ESG was associated with greater decrease in MTV compared to IGB (340.25 ± 297.97 mL vs. 183.00 ± 217.13 mL, P = 0.08), indicting an enhanced effect on satiation through decreased gastric accommodation. Changes in MTV at 3 months did not correlate with %TBWL for either IGB (P = 0.26) or ESG (P = 0.49) but trended toward significance for predicting %TBWL at 6 months for ESG (P = 0.06) but not IGB (P = 0.19). Conclusion: IGB and ESG both induce weight loss but likely through distinct gastric motor function phenotypes, and gastric emptying may predict future weight loss in patients with IGB.
Efficacy and safety of endoscopic ultrasound-guided gastrojejunostomy in patients with malignant gastric outlet obstruction and ascites
Mahmoud, Tala , Law, Ryan , Jaruvongvanich, Veeravich , Ghazi, Rabih , Abusaleh, Rami , Levy, Michael J. , Truty, Mark J. , Law, Ryan J, Storm, Andrew C. , Vargas, Eric J. , Bazerbachi, Fateh , Levy, Michael J. , Chandrasekhara, Vinay , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | May 13, 2022 | Volume: 10 | Issue: 05 | Pages: E670-E678

10.1055/a-1797-9318 | PMID 35571468 Get It

Abstract Background and study aims Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is an endoscopic procedure for treating gastric outlet obstruction (GOO). Limited data exist regarding the safety and efficacy of EUS-GJ in patients with malignant GOO with ascites. Thus, we aimed to study the outcomes and safety of EUS-GJ in GOO patients with vs. without ascites. Patients and methods This is a retrospective cohort study of patients with malignant GOO who underwent successful EUS-GJ at a tertiary care academic center. Primary outcomes included the efficacy and safety of EUS-GJ. Secondary outcomes included 30-day readmission, reintervention, and survival utilizing Kaplan-Meier analysis. Results A total of 55 patients (mean age of 67.0 ± 11.3 years, 40.0 % female) who underwent EUS-GJ, of whom 24 had ascites (small in 22, large in 2) were included. Clinical success was achieved in 91.7 % and 93.5 % (P = 1.00) of patients with and without ascites, respectively. A higher rate of adverse events (AEs) was noted in patients with ascites but this was not statistically significant (37.5 % vs. 19.4 %, P = 0.13). Four patients in the ascites group (16.6 %) developed clinical evidence of peritonitis or sepsis post-EUS-GJ. Eight patients with ascites developed worsening ascites within a month of EUS-GJ. In contrast, only one patient without ascites developed evidence of new ascites. The median survival of patients was not significantly different between the two groups (patients with ascites: 129 days vs. patients without ascites: 180 days, (P = 0.12). Conclusions The efficacy EUS-GJ in the presence of ascites is promising; however, the safety profile remains concerning given the high rate of AEs, specifically peritonitis and sepsis.